References
- Pavone V, Testa G, Gioitta Iachino S, Evola FR, Avondo S, Sessa G. Hypophosphatemic rickets: etiology, clinical features and treatment. Eur J Orthop Surg Traumatol. 2015;25(2):221–226. doi:10.1007/s00590-014-1496-y
- Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009;24(11):1879–1888. doi:10.1359/jbmr.090509
- Carpenter TO, Imel EA, Holm IA, de Beur SM J, Insogna KL. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381–1388. doi:10.1002/jbmr.340
- Haffner D, Emma F, Eastwood DM, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435–455. doi:10.1038/s41581-019-0152-5
- Lambert AS, Zhukouskaya V, Rothenbuhler A, Linglart A. X-linked hypophosphatemia: management and treatment prospects. Joint Bone Spine. 2019;86(6):731–738. doi:10.1016/j.jbspin.2019.01.012
- Rothenbuhler A, Schnabel D, Hogler W, Linglart A. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism. 2020;103S:153892. doi:10.1016/j.metabol.2019.03.009
- Skrinar A, Dvorak-Ewell M, Evins A, et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3(7):1321–1334. doi:10.1210/js.2018-00365
- Zhukouskaya VV, Rothenbuhler A, Colao A, et al. Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia. Endocr Connect. 2020;9(2):144–153. doi:10.1530/EC-19-0481
- Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557–565. doi:10.1200/JCO.2015.63.0830
- Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016;10:711–725.
- Scotte F. The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer. Oncologist. 2012;17(Suppl 1):23–30. doi:10.1634/theoncologist.2012-S1-23
- Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2017;23(8):859–867. doi:10.18553/jmcp.2017.16272
- Prèvot G, Stevens J, Leguay A, Brier T, Meijer J, Aguilaniu B. OPALE accompagnement des patients traitÈs pour une fibrose pulmonaire idiopathique. Rev Mal Respir. 2019;36:A142.
- Varni JW, Seid M, Kurtin PS. PedsQL 4.0 : Reliability and Validity of the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scales in Healthy and Patient Populations. Medical Care. 2001;39(8):800–812.
- Pinquart M. Self-esteem of children and adolescents with chronic illness: a meta-analysis. Child Care Health Dev. 2013;39(2):153–161. doi:10.1111/j.1365-2214.2012.01397.x